SV7 Impact Medicine Fund LP
SEC CIK 1780602 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | 10% | 1.30M | $10.00M | — | 4 | 2021-10-26 | 2021-10-26 |
Most active insiders at XLO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Shannon James Samuel | Dir | $43.9K | — |
| 2 | Frankenfield Christopher James | CFO | — | $4,499 |
| 3 | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | — | $1,169 |
| 4 | Luptakova Katarina | Chief MEDICAL Off | — | — |
| 5 | Russo Rene | Pres AND CEO, Dir | — | — |
SV7 Impact Medicine Fund LP made no open-market trades at XLO in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAI | 2021-11-03 | 2021-10-26 | XLO | Xilio Therapeutics, Inc. | SV7 Impact Medicine Fund LP | 10% | C - Cnv Deriv | — | +1.30M | 1.30M | New | — |
| DMA | 2021-11-03 | 2021-10-26 | XLO | Xilio Therapeutics, Inc. | SV7 Impact Medicine Fund LP | 10% | C - Cnv Deriv | — | +1.30M | 1.30M | New | — |
| DA | 2021-11-03 | 2021-10-26 | XLO | Xilio Therapeutics, Inc. | SV7 Impact Medicine Fund LP | 10% | P - Purchase | $16.00 | +312.5K | 1.61M | +24% | +$5.00M |
| DAI | 2021-11-03 | 2021-10-26 | XLO | Xilio Therapeutics, Inc. | SV7 Impact Medicine Fund LP | 10% | P - Purchase | $16.00 | +312.5K | 1.61M | +24% | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations